(Q36778741)

16 August 2017

1 reference

title

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications (English)

1 reference

16 August 2017

1 reference

1 reference

Matthias Miederer

1

1 reference

16 August 2017

David A Scheinberg

series ordinal

2

1 reference

16 August 2017

Michael R McDevitt

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

23 April 2008

1 reference

Advanced Drug Delivery Reviews

16 August 2017

1 reference

16 August 2017

60

1 reference

16 August 2017

12

1 reference

16 August 2017

1371-1382

1 reference

Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Cancer radioimmunotherapy with alpha-emitting nuclides

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Production of actinium-225 for alpha particle mediated radioimmunotherapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Cyclotron production of Ac-225 for targeted alpha therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Targeting of radio-isotopes for cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Tumor therapy with targeted atomic nanogenerators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Improved in vivo stability of actinium-225 macrocyclic complexes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Efforts to control the errant products of a targeted in vivo generator

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

Breaking Chemoresistance and Radioresistance with [213Bi]anti-CD45 Antibodies in Leukemia Cells

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3630456

A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: a matrix approach

4 December 2018

1 reference

12 December 2020

Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters

1 reference

12 December 2020

Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors

1 reference

12 December 2020

Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy

1 reference

12 December 2020

Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49

1 reference

12 December 2020

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

12 December 2020

Design and synthesis of 225Ac radioimmunopharmaceuticals

1 reference

12 December 2020

A case of accidental inhalation of protactinium-231 and actinium-227

1 reference

12 December 2020

The Metabolism of Actinium in the Rat

1 reference

12 December 2020

The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy

1 reference

12 December 2020

The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225-Ac in tumor-bearing mice. The ISOLDE Collaboration

1 reference

12 December 2020

Radioimmunotherapy with alpha-emitting nuclides

1 reference

12 December 2020

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry

1 reference

12 December 2020

Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates

1 reference

12 December 2020

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation

1 reference

12 December 2020

Comparison of 225actinium chelates: tissue distribution and radiotoxicity

1 reference

12 December 2020

The metabolism of Ac227 and its daughters Th227 and Ra223 by rats

1 reference

12 December 2020

Production of Ac-225 from Th-229 for targeted alpha therapy

1 reference

12 December 2020

Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications

1 reference

12 December 2020

10.1016/J.ADDR.2008.04.009

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

18514364

1 reference